A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Incyte said on Monday its experimental combo therapy helped patients with a type of blood cancer live longer without their ...

Incyte said on Monday its experimental combo therapy helped patients live longer without their disease worsening in a late-stage study of a type of blood cancer, sending its shares up about 3% in ...

The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

Thomas M. Habermann, MD, is a hematologist with the Mayo Clinic in Rochester, Minnesota. A member of the Lymphoma Research Foundation Scientific Advisory Board, Habermann is well known as the lead ...

Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I ...

Immunomedics IMMU, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, ...